PHATHOM PHARMACEUTICALS, INC. Convertible Notes Payable, Current
PHATHOM PHARMACEUTICALS, INC. (PHAT) had Convertible Notes Payable, Current of $95.23 million as of 2019-09-30, per its 10-Q filed 2019-11-25.
Discontinued › Balance Sheet
us-gaap:ConvertibleNotesPayableCurrent · last filed 2020-03-19
- 2019-09-30: Convertible Notes Payable, Current $95.23M.
- 2018-12-31: Convertible Notes Payable, Current $1.95M.
| Period end | Convertible Notes Payable, Current |
|---|---|
| 2019-09-30 | $95.23M 10-Q · filed 2019-11-25 |
| 2018-12-31 | $1.95M 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |